Home > Press > Newbridge Securities Releases Quarterly Update of Inside Nanotechnology
Abstract:
Newbridge Securities Corporation today announced the release of the first quarter 2007 issue of Inside Nanotechnology. This 32-page report is the eleventh quarterly installment in the series, which covers general developments affecting the commercialization of nanotechnology and in-depth analysis of the 24 companies that constitute the Newbridge Nanotechnology Index (NYSE Arca: NNIX). In this issue, we discuss the recent removal of one company from the NNIX, ASTM's work in developing standards for nanotech, and a report from ICF on the U.S. Federal environmental, health and safety research program.
"The NNIX gained 7.2% in Q4, narrowly exceeding the 6.9% rise in the NASDAQ," said J. Andrew Braswell, Equity Analyst for Newbridge Research and lead author of Inside Nanotechnology. "However, the NNIX lagged the broad indexes in full-year performance. Speculative interest in nanotech appears to be at a cyclical low level, and valuations across much of our coverage universe remain attractive." For each company, the report provides a recap of relevant news from the preceding quarter, along with analysis and commentary that helps investors discern the future leaders of this dynamic, emerging space. While the current universe of publicly traded, pure play nanotechnology companies remains relatively narrow, there are many exciting start-ups that appear poised for IPOs in the next few years. Furthermore, nano R&D initiatives ongoing at large, multinational corporations in industries such as chemicals, consumer electronics and semiconductors are beginning to determine the competitive advantages of tomorrow. "Going forward, nanotechnology will become increasingly relevant to all investors, growth-oriented or otherwise," said Braswell.
####
About Newbridge Securities
Newbridge is a full-service securities brokerage firm (Member: NASD & SIPC) and a subsidiary of Newbridge Financial, Inc., an integrated financial services company. The Newbridge Institutional Research department specializes in the analysis and coverage of companies that have a strategic focus on nanotechnology. More information is available at our websites http://www.newbridgereports.com and http://www.newbridgesecurities.com .
For important disclosures please visit: http://www.newbridgesecurities.com/research_rpt_discl.html. Additional information is available upon request.
For more information, please click here
Contacts:
David M. Keiter
Director of Research
954-334-3450 x115
Copyright © Market Wire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||